Anti-angiogenic agents in ovarian cancer: past, present, and future
Author:
Funder
Ann Rife Cox Chair in Gynecology
Judy Reis (Al Pisani) Ovarian Cancer Research Fund
Publisher
Elsevier BV
Subject
Oncology,Hematology
Link
http://academic.oup.com/annonc/article-pdf/27/suppl_1/i33/19447050/mdw093.pdf
Reference46 articles.
1. Latest research and treatment of advanced-stage epithelial ovarian cancer;Coleman;Nat Rev Clin Oncol,2013
2. Long-term survival in a phase III, randomised study of topotecan versus paclitaxel in advanced epithelial ovarian carcinoma;ten Bokkel Huinink;Ann Oncol,2004
3. Long-term survival advantage for women treated with pegylated liposomal doxorubicin compared with topotecan in a phase 3 randomized study of recurrent and refractory epithelial ovarian cancer;Gordon;Gynecol Oncol,2004
4. Trabectedin plus pegylated liposomal doxorubicin in recurrent ovarian cancer;Monk;J Clin Oncol,2010
5. US Food and Drug Administration. Bevacizumab solution in combination with paclitaxel. http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm423159.htm(20 November 2015, date last accessed).
Cited by 119 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. ANGPTL4 regulates ovarian cancer progression by activating the ERK1/2 pathway;Cancer Cell International;2024-02-04
2. Efficacy and safety of VEGF/VEGFR inhibitors for platinum-resistant ovarian cancer: a systematic review and meta-analysis of randomized controlled trials;BMC Women's Health;2024-01-13
3. Diagnosis and treatment of ovarian cancer in the light of modern molecular genetic achievements;Siberian journal of oncology;2023-11-15
4. Aptamers as Potential Therapeutic Tools for Ovarian Cancer: Advancements and Challenges;Cancers;2023-11-06
5. Tyrosine kinase inhibitors (TKIs) for ovarian cancer treatment: from organic to inorganic chemotherapeutics towards selectivity—a perspective overview;BioMetals;2023-11-06
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3